Q12. Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world, and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug, as there is significant market demand for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest taking shortcuts to expedite the clinical trials and obtain requisite approvals. These include manipulating data to exclude negative outcomes, selectively reporting positive results, foregoing the process of informed consent, and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, but at the same time, he realises that meeting the targets is impossible without using these means.
What would you do in such a situation? Examine your options and consequences in light of the ethical questions involved. How can data ethics and drug ethics save humanity at large in such a scenario? (Answer in 250 words) Introduction: “A good decision is based on knowledge and not on numbers.” This quote by …








